Overview – Nitto Avecia

Unmatched oligonucleotide experience

Nitto Avecia was the first CDMO to serve the oligonucleotide therapeutic market. Since then, we have manufactured more than 1,200 oligonucleotide sequences and developed the most extensive late-phase portfolio of any oligonucleotide CDMO. This experience gives our analytical, manufacturing, and quality teams unparalleled expertise to make your oligonucleotide program a success.

End-to-end solution

In partnership with Nitto Avecia Pharma Services, Nitto Avecia is the first CDMO that offers a comprehensive, end-to-end oligonucleotide solution. This offers the advantage of a single, expert partner handling the entire process—from drug substance through drug product manufacturing—with flexible solutions and consistent reliability and quality.

Learn more about Nitto Avecia Pharma Services

State-of-the-art facilities

Our FDA-inspected, GMP-compliant facilities in Massachusetts and Ohio are optimized to meet the specialized needs of the oligonucleotide market, from pre-clinical through commercial production. We continually expand and update our technical capabilities to meet our customers’ evolving needs.

Learn more about our facilities

Creating wonders, generating value

At Nitto Avecia, we relentlessly pursue products, processes, and technologies that create value for our customers. As part of Nitto Group, we share a common vision: “Creating Wonders.” Each of us, every day, works to create wonders with the power to change the world.

Learn more about the Nitto Group philosophy